Mean DAS28-4(ESR), CDAI and HAQ-DI scores in patients who switched treatment regimens during the LTE studies
| Mono→combo switchers | Combo→mono switchers | ||||
| Tofacitinib 5 mg twice daily n=46* | Tofacitinib 10 mg twice daily n=82† | Tofacitinib 5 mg twice daily n=97‡ | Tofacitinib 10 mg twice daily n=255§ | ||
| Mean DAS28-4(ESR) (SD) | 3 months before treatment switch | 3.95 (1.70) | 4.35 (1.56) | 3.47 (1.39) | 3.27 (1.23) |
| At treatment switch | 4.11 (1.76) | 4.73 (1.67) | 3.27 (1.21) | 3.17 (1.13) | |
| 3 months after treatment switch | 4.13 (1.71) | 4.41 (1.60) | 3.37 (1.31) | 3.16 (1.13) | |
| 6 months after treatment switch | 3.91 (1.63) | 4.35 (1.60) | 3.29 (1.32) | 3.06 (1.27) | |
| 12 months after treatment switch | 3.44 (1.51) | 4.24 (1.46) | 3.53 (1.29) | 3.20 (1.25) | |
| Mean CDAI (SD) | 3 months before treatment switch | 15.87 (18.83) | 16.15 (13.26) | 8.33 (9.85) | 7.86 (8.68) |
| At treatment switch | 19.08 (16.47) | 20.67 (14.67) | 7.44 (9.40) | 6.96 (7.29) | |
| 3 months after treatment switch | 16.65 (14.17) | 17.47 (14.12) | 7.91 (10.39) | 6.78 (6.86) | |
| 6 months after treatment switch | 14.26 (11.75) | 17.13 (15.46) | 7.74 (9.83) | 6.71 (8.24) | |
| 12 months after treatment switch | 9.97 (10.38) | 15.39 (12.32) | 7.88 (7.79) | 7.10 (7.73) | |
| Mean HAQ-DI (SD) | 3 months before treatment switch | 0.81 (0.85) | 1.03 (0.70) | 0.82 (0.68) | 0.68 (0.66) |
| At treatment switch | 0.94 (0.76) | 1.00 (0.71) | 0.69 (0.66) | 0.65 (0.64) | |
| 3 months after treatment switch | 0.89 (0.72) | 0.93 (0.74) | 0.75 (0.65) | 0.63 (0.64) | |
| 6 months after treatment switch | 0.77 (0.69) | 0.96 (0.73) | 0.62 (0.60) | 0.60 (0.64) | |
| 12 months after treatment switch | 0.73 (0.67) | 0.89 (0.77) | 0.68 (0.64) | 0.64 (0.65) | |
*3 months before treatment switch n=35 (34 for CDAI), at treatment switch n=46 (45 for CDAI, 44 for DAS28-4(ESR)), 3 months after treatment switch n=44 (42 for CDAI, 41 for DAS28-4(ESR)), 6 months after treatment switch n=38 (37 for CDAI, 36 for DAS28-4(ESR)), 12 months after treatment switch n=25.
†3 months before treatment switch n=67 (66 for DAS28-4(ESR) and HAQ-DI), at treatment switch n=82, 3 months after treatment switch n=78 (77 for DAS-284(ESR)), 6 months after treatment switch n=67, 12 months after treatment switch n=48 (47 for CDAI and HAQ-DI).
‡3 months before treatment switch n=84, at treatment switch n=97, 3 months after treatment switch n=90 (89 for DAS28-4(ESR) and HAQ-DI), 6 months after treatment switch n=87, 12 months after treatment switch n=74 (73 for DAS28-4(ESR) and CDAI).
§3 months before treatment switch n=210 (209 for HAQ-DI), at treatment switch n=255, 3 months after treatment switch n=242 (241 for HAQ-DI and 238 for DAS28-4(ESR)), 6 months after treatment switch n=218, 12 months after treatment switch n=190 (189 for DAS28-4(ESR)).
CDAI, Clinical Disease Activity Index; DAS28-4(ESR), Disease Activity Score in 28 joints, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire-Disability Index; LTE, long-term extension.